Targeting of 111in-labeled dendritic cell human vaccines improved by reducing number of cells

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1525-1533

  Aarntzen, Erik H J G ^a,b   Srinivas, Mangala ^a   Bonetto, Fernando ^f   Cruz, Luis J ^a,c   Verdijk, Pauline ^a,d   Schreibelt, Gerty ^a   Van De Rakt, Mandy ^a   Lesterhuis, W Joost ^b,e   Van Riel, Maichel ^b   Punt, Cornelius J A ^e   Adema, Gosse J ^a   Heerschap, Arend ^b   Figdor, Carl G ^a   Oyen, Wim J ^b   De Vries, I Jolanda M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; DENDRITIC CELL VACCINE IN 111; FLUORINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOCYANIN; IMIQUIMOD; INTERLEUKIN 2; MONOPHENOL MONOOXYGENASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 8 QUINOLINOL; 8 QUINOLINOL INDIUM; CANCER VACCINE; DRUG DERIVATIVE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL MIGRATION; CLINICAL TRIAL; DENDRITIC CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCINTIGRAPHY; ADOLESCENT; AGED; CANCER STAGING; CELL MOTION; CHEMISTRY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOLOGY; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; CANCER VACCINES; CELL MOVEMENT; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; OXYQUINOLINE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84875183933     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1879     Document Type: Article

References (29)

1. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77.
2. Srinivas M, Aarntzen EH, Bulte JW, Oyen WJ, Heerschap A, de Vries IJ, et al. Imaging of cellular therapies.Adv DrugDelivRev 2010;62:1080-93.
3. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003;198:615-21.
4. Tripp CH, Ebner S, Ratzinger G, Romani N, Stoitzner P. Conditioning of the injection site with CpG enhances the migration of adoptively transferred dendritic cells and endogenous CD8+ T-cell responses. J Immunother 2010;33:115-25.
5. Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ, Figdor CG. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther 2008;8:865-74.
6. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005;5:617-28.
7. Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol 2006;4:217-28.
8. Bonetto F, Srinivas M, Weigelin B, Cruz LJ, Heerschap A, Friedl P, et al. A large-scale (19) F MRI-based cell migration assay to optimize cell therapy. NMR Biomed 2012;25:1095-103.
9. Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, van Rossum MM, et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell based vaccination in metastatic melanoma. Cancer Res 2012;72:6102-10.
10. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011;17:5725-35.
11. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003;9:5091-100.
12. Srinivas M, Heerschap A, Ahrens ET, Figdor CG, de Vries IJ. (19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol 2010;28: 363-70.
13. Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, et al. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3′-fluoro-3′-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A 2011;108:18396-9.
14. DeVries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12-7.
15. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM,et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009;15:2531-40.
16. Verdijk P, Scheenen TW, Lesterhuis WJ, Gambarota G, Veltien AA, Walczak P, et al. Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer 2007;120:978-84.
17. Mellman I, Nussenzweig M. Retrospective. Ralph M. Steinman (1943-2011). Science 2011;334:466.
18. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2012;363:411-22.
19. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
20. Celli S, Day M, Muller AJ, Molina-Paris C, Lythe G, Bousso P. How many dendritic cells are required to initiate a T cell response? Blood 2012;120:3945-8.
21. Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171: 6275-82.
22. Geissmann F, Dieu-Nosjean MC, Dezutter C, Valladeau J, Kayal S, Leborgne M, et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 2002;196:417-30.
23. Toetsch S, Olwell P, Prina-Mello A, Volkov Y. The evolution of chemotaxis assays from static models to physiologically relevant platforms. Integr Biol (Camb) 2009;1:170-81.
24. Srinivas M, Cruz LJ, Bonetto F, Heerschap A, Figdor CG, de Vries IJ. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials 2010;31:7070-7.
25. Tal O, Lim HY, Gurevich I, Milo I, Shipony Z, Ng LG, et al. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J Exp Med 2011;208:2141-53.
26. Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. Cancer Biother Radiopharm 2011;26:407-15.
27. Engell-Noerregaard L, Hansen TH, Andersen MH, thor SP, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009;58:1-14.
28. van den Berg JH, Nujien B, Beijnen JH, Vincent A, van Tinteren H, Kluge J, et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009;20:181-9.
29. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigenspecific T-cell responses in melanoma patients. Cancer Res 2013;73: 1063-75.